Valuation: Alvotech

Market Cap 125.82Cr 110.13Cr 101.66Cr 95Cr 178.67Cr 12TCr 181.87Cr 1.22TCr 473.41Cr 5.87TCr 472.7Cr 462.14Cr 20TCr P/E 2026 *
9.22x
P/E 2027 * 8.45x
Enterprise Value 235.72Cr 206.32Cr 190.46Cr 177.66Cr 334.74Cr 22TCr 340.73Cr 2.28TCr 886.93Cr 11TCr 885.59Cr 865.81Cr 38TCr EV / Sales 2026 *
3.55x
EV / Sales 2027 * 3x
Free-Float
41.72%
Yield 2026 *
-
Yield 2027 * -
1 day-5.95%
1 week-4.66%
Current month+3.57%
1 month+3.57%
3 months+11.90%
6 months-29.98%
Current year-32.16%
1 week 3.45
Extreme 3.45
3.77
1 month 2.94
Extreme 2.94
4.59
Current year 2.94
Extreme 2.94
5.58
1 year 2.94
Extreme 2.94
9.94
3 years 2.94
Extreme 2.94
18
5 years 2.94
Extreme 2.94
18
10 years 2.94
Extreme 2.94
18
Manager TitleAgeSince
Chief Executive Officer 55 01/03/2026
Director of Finance/CFO 48 10/07/2025
Chief Tech/Sci/R&D Officer - 01/01/2023
Director TitleAgeSince
Chairman 56 01/01/2019
Director/Board Member 64 01/01/2019
Director/Board Member 58 01/01/2019
Date Insider Type Main position Quantity % Market Cap.
01/04Free

Chief Executive Officer

1,17,271 0.0355%
01/04Buy

Founder

3,18,000 0.0963%
01/04Sell

Founder

3,18,000 0.0963%
Change 5-day change 1-year change 3-year change Capi.($)
-5.95%-4.66%-61.93%-49.57% 125.82Cr
+1.15%+9.07%-3.67%+4.36% 4.66TCr
-2.77%+10.48%+409.05%+600.11% 4.1TCr
-0.03%+12.81%+22.61%-14.04% 3.23TCr
-1.73%+3.20%+17.72%+59.83% 3.22TCr
-3.29%+2.85%+13.80%+30.30% 2.55TCr
+1.15%+11.79% - - 1.64TCr
-0.96%+11.85%+68.73%+120.51% 1.53TCr
+0.56%+8.00%+12.65%+21.35% 1.36TCr
-1.74%+4.34%+100.68%+93.25% 1.33TCr
Average -1.41%+8.17%+64.41%+96.23% 2.37TCr
Weighted average by Cap. -1.00%+10.25%+93.72%+137.24%

Financials

2026 *2027 *
Net sales 66Cr 58Cr 54Cr 50Cr 94Cr 6.27TCr 96Cr 642.99Cr 249.63Cr 3.1TCr 249.25Cr 243.68Cr 11TCr 79Cr 69Cr 64Cr 60Cr 112.52Cr 7.49TCr 114.53Cr 767.94Cr 298.14Cr 3.7TCr 297.68Cr 291.04Cr 13TCr
Net income 16Cr 14Cr 13Cr 12Cr 23Cr 1.56TCr 24Cr 159.87Cr 62Cr 769.64Cr 62Cr 61Cr 2.68TCr 13Cr 12Cr 11Cr 10Cr 19Cr 1.27TCr 19Cr 129.93Cr 50Cr 625.47Cr 50Cr 49Cr 2.18TCr
Net Debt 109.9Cr 96Cr 89Cr 83Cr 156.07Cr 10TCr 158.86Cr 1.07TCr 413.52Cr 5.13TCr 412.89Cr 403.67Cr 18TCr 111.94Cr 98Cr 90Cr 84Cr 158.97Cr 11TCr 161.81Cr 1.08TCr 421.2Cr 5.22TCr 420.56Cr 411.17Cr 18TCr
Logo Alvotech
Alvotech SA is a biotechnology company. The Company is focused on the development and manufacture of biosimilar medicines for patients globally. It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). It has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.
Employees
1,279
Date Price Change Volume
30/26/30 $3.690 -0.81% 8,53,797
29/26/29 $3.720 +1.09% 6,90,356
26/26/26 $3.680 +5.75% 9,91,865
25/26/25 $3.480 -5.95% 10,88,290
24/26/24 $3.700 0.00% 7,87,083
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
3.720USD
Average target price
14.60USD
Spread / Average Target
+292.47%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALVO Stock